A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC)

[1]  C. Genestie,et al.  Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers , 2017, Clinical genetics.

[2]  K. Garg,et al.  Immunohistochemistry for 2-Succinocysteine (2SC) and Fumarate Hydratase (FH) in Cutaneous Leiomyomas May Aid in Identification of Patients With HLRCC (Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome) , 2016, The American journal of surgical pathology.

[3]  Aikseng Ooi,et al.  Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1). , 2015, Biochemical Society transactions.

[4]  W. Linehan,et al.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment , 2014, Familial Cancer.

[5]  M. Simpson,et al.  Germline FH mutations presenting with pheochromocytoma. , 2014, The Journal of clinical endocrinology and metabolism.

[6]  W. Linehan,et al.  Hereditary leiomyomatosis and renal cell carcinoma , 2014, International journal of nephrology and renovascular disease.

[7]  P. Rustin,et al.  Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. , 2014, Human molecular genetics.

[8]  C. Tan,et al.  Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC) , 2014, Familial Cancer.

[9]  Lars Egevad,et al.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia , 2013, The American journal of surgical pathology.

[10]  L. Aaltonen,et al.  Aberrant succination of proteins in fumarate hydratase‐deficient mice and HLRCC patients is a robust biomarker of mutation status , 2011, The Journal of pathology.

[11]  H. Lehtonen,et al.  Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics , 2011, Familial Cancer.

[12]  L. Thomas,et al.  Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma , 2011, Journal of Medical Genetics.

[13]  L. Hoefsloot,et al.  Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis , 2011, Clinical genetics.

[14]  C. de Bazelaire,et al.  Hereditary renal cancer syndromes: an update of a systematic review. , 2010, European urology.

[15]  Peter A Pinto,et al.  The clinical implications of the genetics of renal cell carcinoma. , 2009, Urologic oncology.

[16]  W. Linehan,et al.  Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. , 2008, Archives of dermatology.

[17]  Jean-Pierre Bayley,et al.  The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency , 2008, BMC Medical Genetics.

[18]  L. Aaltonen,et al.  Increased risk of cancer in patients with fumarate hydratase germline mutation , 2005, Journal of Medical Genetics.

[19]  P. Choyke,et al.  Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer , 2005, Journal of Medical Genetics.

[20]  A. Rowan,et al.  Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. , 2005, Archives of dermatology.

[21]  P. Choyke,et al.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. , 2003, American journal of human genetics.

[22]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[23]  K. Nathanson,et al.  Hereditary kidney cancer syndromes. , 2014, Advances in chronic kidney disease.